Astex Pharmaceuticals (ASTX -2.6%) slips despite presenting data which suggests the HSP90...

|About: Astex Pharmaceuticals, Inc. (ASTX)|By:, SA News Editor

Astex Pharmaceuticals (ASTX -2.6%) slips despite presenting data which suggests the HSP90 inhibitor AT13387 delayed the emergence of resistance in mice in a preclinical model of mutant BRAF melanoma. The mice were treated with vemurafenib alone and in combination with AT13387. Mice which received the combination treatment did not exhibit tumor regrowth. (PR)